<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989362</url>
  </required_header>
  <id_info>
    <org_study_id>JTX-2011-201</org_study_id>
    <nct_id>NCT03989362</nct_id>
  </id_info>
  <brief_title>Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer</brief_title>
  <acronym>EMERGE</acronym>
  <official_title>Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jounce Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jounce Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and
      ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to
      evaluate safety and efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vopratelimab (JTX-2011) is an agonist monoclonal antibody that specifically binds to the
      Inducible CO-Stimulator of T cells (ICOS) to generate an anti-tumor immune response. This is
      a Phase 2, open label study to evaluate the safety and efficacy of vopratelimab in
      combination with ipilimumab in adult subjects with advanced and/or refractory non-small cell
      lung cancer and urothelial cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% subjects with overall response (OR)</measure>
    <time_frame>34 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% subjects with adverse events (AEs)</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% subjects with serious adverse events (SAEs)</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% subjects with clinically significant change from baseline in clinical laboratory tests</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% subjects with anti-drug antibodies (ADA) to treatment</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of subjects with neutralizing antibodies (NAb) to treatment</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of subjects with clinically significant changes in electrocardiogram (ECG) measurements</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in target lesions from baseline</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during specific time points</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (DOR)</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark progression free survival (PFS)</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median PFS</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>34 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">452</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>LM1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by intravenous (IV) infusion administered in combination with ipilimumab by IV infusion in NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UM1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LT2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UT2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vopratelimab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>LM1</arm_group_label>
    <arm_group_label>LM2</arm_group_label>
    <arm_group_label>LT1</arm_group_label>
    <arm_group_label>LT2</arm_group_label>
    <arm_group_label>UM1</arm_group_label>
    <arm_group_label>UM2</arm_group_label>
    <arm_group_label>UT1</arm_group_label>
    <arm_group_label>UT2</arm_group_label>
    <other_name>JTX-2011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>LM1</arm_group_label>
    <arm_group_label>LM2</arm_group_label>
    <arm_group_label>LT1</arm_group_label>
    <arm_group_label>LT2</arm_group_label>
    <arm_group_label>UM1</arm_group_label>
    <arm_group_label>UM2</arm_group_label>
    <arm_group_label>UT1</arm_group_label>
    <arm_group_label>UT2</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to participate and comply with all trial requirements and able to
             provide signed and dated informed consent prior to initiation of any trial procedures

          2. Male or female ≥ 18 years of age

          3. Locally advanced, inoperable or metastatic NSCLC or urothelial cancer, with evaluable
             or measurable disease, according to RECIST v1.1, with at least one measurable lesion

          4. Prior treatment with a PD-1/PD -L1 inhibitor for at least 3 months

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          6. Predicted life expectancy ≥ 3 months

          7. Have laboratory values in accordance with the study protocol

          8. If medical history of the following, case should be reviewed with the Medical Monitor:
             prior biliary tract disorders (as based on Hepatobiliary system organ class high level
             terms of obstructive bile duct disorders, hepatic vascular disorders, structural and
             other bile duct disorders) or portal hypertension and/or hepatic vascular disorders

          9. Women of child-bearing potential (WOCBP): negative serum pregnancy test within 72
             hours prior to planned C1D1 and a negative urine pregnancy test on C1D1 and any
             subsequent study drug administration day

         10. WOCBP and males whose partners are WOCBP must agree to use a highly effective method
             of birth control throughout their participation and for 5 months following the last
             study drug administration. Highly effective methods of birth control are defined as
             those, alone or in combination, that result in a low failure rate (i.e., less than 1
             percent per year) when used consistently and correctly. For subjects using a hormonal
             contraceptive method, information regarding the product under evaluation and its
             potential effect on the contraceptive should be addressed.

        Exclusion Criteria:

          1. Concurrent anticancer treatment (either approved or investigational, excluding
             radiation therapy)

          2. Prior anticancer therapies within the timeframes specified below, or ongoing toxicity
             from prior therapy &gt; Grade 1 according to the Common Terminology Criteria for Adverse
             Events (CTCAE) v5.0. Exceptions include &gt; Grade 1 toxicities that, in the opinion of
             the Investigator, should not exclude the subject (e.g., alopecia) and are approved by
             the Medical Monitor:

               1. Biologic therapy, including immunotherapy, within 21 days prior to C1D1

               2. Chemotherapy within 21 days (42 days for mitomycin or nitrosoureas) prior to C1D1

               3. Anti-CTLA-4 or anti-ICOS therapy at any time

               4. Chimeric antigen receptor T-cell therapy at any time

               5. Organ transplantation, including allogeneic or autologous stem-cell
                  transplantation, at any time

          3. Major surgery (excluding minor procedures, e.g., placement of vascular access, biopsy,
             etc.) within 4 weeks prior to C1D1

          4. Live vaccines within 30 days prior to C1D1 (inactivated vaccines are allowed; seasonal
             vaccines should be up to date prior to C1D1)

          5. History of immune-related adverse events (irAEs) leading to treatment discontinuation.
             Subjects who discontinued prior immunotherapies for irAEs that are well controlled
             with appropriate treatment may be enrolled if approved by the Medical Monitor

          6. Any active disease, including primary or acquired immunodeficiency, requiring systemic
             immunosuppressive therapy equivalent to ≥10 mg prednisone per day within 7 days prior
             to C1D1. Exception: inhaled or topical steroids and adrenal replacement doses are
             permitted in the absence of active autoimmune disease as well as a one-time dose of
             immunosuppressive agents used prophylactically for contrast allergies

          7. Known severe intolerance to or life-threatening hypersensitivity reactions to
             humanized monoclonal antibodies or intravenous immunoglobulin preparations; history of
             anaphylaxis; or known allergy to any of the study medications, their analogues, or
             excipients in the various formulations of any agent

          8. Brain metastases, leptomeningeal disease, or spinal cord compression not definitively
             treated with surgery or radiation

          9. Prior whole brain radiation

         10. Concurrent second malignancy at other sites that requires treatment or, in the
             judgment of the Investigator, may require treatment within the next year. Concurrent
             malignancies that do not require treatment and are clinically stable are allowed.
             Prior malignancies are allowed as long as the subject is not receiving specific
             treatment other than hormonal therapy and, in the judgment of the Investigator, is
             unlikely to have a recurrence

         11. Active and clinically relevant bacterial, fungal, or viral infection, including known
             Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not required)

         12. Women who are pregnant or breastfeeding

         13. History of symptomatic cardiac disease that is unresponsive to surgical or medical
             management

         14. Any medical or social condition that, in the opinion of the Investigator, might place
             a subject at increased risk, affect compliance, or confound safety or other clinical
             trial data interpretation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Hooper, MD, FAAP</last_name>
    <role>Study Director</role>
    <affiliation>Jounce Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel McComb</last_name>
    <email>EMERGE@jouncetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Berz</last_name>
      <email>dberz@bhcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>David Berz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Xia, MD</last_name>
    </contact>
    <contact_backup>
      <email>Bing.Xia@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bing Xia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Guarino, MD</last_name>
      <email>michael.j.guarino@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guarino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists Sarasota Cattlemen</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Marlene and Stewart Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Mannuel, MD</last_name>
    </contact>
    <contact_backup>
      <email>hmannuel@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Heather Mannuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Gainor, MD</last_name>
      <email>jgainor@partners.org</email>
    </contact>
    <investigator>
      <last_name>Justin Gainor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramaswamy Govindan, MD</last_name>
      <email>rgovindan@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ramaswamy Govindan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Kirshner, MD</last_name>
      <email>kirsel@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Eli Kirshner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Scheff, MD</last_name>
      <email>rjs2002@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ronald</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ronald Scheff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Victor, MD</last_name>
      <email>adrienne_victor@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Adrienne Victor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Clinton</city>
        <state>North Carolina</state>
        <zip>28328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samer Kasbari, MD</last_name>
      <email>skasbari@cancersmoc.com</email>
    </contact>
    <investigator>
      <last_name>Samer Kasbari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Pennell, MD</last_name>
    </contact>
    <contact_backup>
      <email>penneln@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nathan Pennell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gene Finley, MD</last_name>
      <email>gene.finley@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Gene Finley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Azzoli, MD</last_name>
      <email>CAzzoli@Lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Azzoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Johnson, MD</last_name>
      <email>melissa.johnson@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Altan, M.D.</last_name>
      <email>maltan@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Mehmet Altan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of The Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Alvarez</last_name>
      <phone>210-450-5893</phone>
      <email>alvarezg1@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Chethan Ramamurthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gracie Hockenberry</last_name>
      <phone>434-297-7784</phone>
      <email>mgt4n@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Gentzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Zawisza</last_name>
      <phone>416-946-2913</phone>
      <email>Dianne.zawisza@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Natasha Leighl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Owen, MD</last_name>
      <email>scott.owen@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Scott Owen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Institute of Cardiology and Respirology of Quebec</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Fortin</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2639</phone_ext>
      <email>brigitte.fortin@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Yves Lacasse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICOS</keyword>
  <keyword>ICOS agonist monoclonal antibody</keyword>
  <keyword>JTX-2011</keyword>
  <keyword>Vopratelimab</keyword>
  <keyword>Anti-CTLA-4</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>EMERGE</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immuno-Oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Urothelial Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

